NCT06916000

Assessment of PENG Block as a Part of Multimodal Analgesia Following Hip Surgeries.

Effect of Ultrasound Guided Pericapsular Nerve Group (PENG) Block on Perioperative Pain Management in Patients Undergoing Hip Arthroplasty

• Status: Active Not Recruiting
• Phase: N/A
• Study type: Interventional
• Enrollment: 50 (actual)
• Sponsor: Ain Shams University · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

to study the effect of Pericapsular nerve group (PENG) block as a part of multimodal analgesia regimen for hip arthroplasties

Detailed description

PENG block is a novel block described by Giron-Arango in 2018 to anesthesize the anterior hip capsule as it is supplied by branches from femoral, obturator and accessory obturator nerves, sparing motor function is an additional significance So currently the block is used to reduce post operative opioid consumption, delay time rescue analgesia, facilitate positioning for spinal anesthesia for hip surgeries and to accelerate mobility and so hospital discharge saving this vulnerable group of patient from any hospital acquired pneumonia, decreasing hospital stays, and improving recovery times would provide valuable insights into its cost-effectiveness and long-term benefits for healthcare system Our primary outcome to be studied is pain assessment via Numer Rating Scale over 24 hours postoperatively, in addition to to secondary outcomes including the aforementioned advantages.

Conditions

• Anesthesia

Interventions

Type	Name	Description
DRUG	Pericapsular nerve group (PENG) block	As a part of multimodal analgesia patients will receive 20 ml of 0.25% bupivcacaine according to the technique described by Giron-Arango. All patients will receive the same analgesic protocol, which included IV paracetamol 1000 mg BID and NSAIDs if no contra-indication; PO celecoxib 100 mg BID. Also if needed nalbuphine 5 mg IV will be given as bolus demand dose and when the NRS pain score was equal to or greater than 4 points.
OTHER	Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.	Patients will receive only other multimodal analgesics including LCFN block via 10 ml of 0.25% bupivacaine.

Timeline

• Start date: 2024-06-27
• Primary completion: 2025-06-01
• Completion: 2025-06-01
• First posted: 2025-04-08
• Last updated: 2025-04-08

Locations

1 site across 1 country: Egypt